Načítá se...
Selinexor in relapsed/refractory multiple myeloma
Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite significant advances over the past decade, with the advent of multiple new classes of anti-myeloma agents, including immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies, patients ultimately relapse. Sel...
Uloženo v:
| Vydáno v: | Ther Adv Hematol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7285937/ https://ncbi.nlm.nih.gov/pubmed/32566115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720930629 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|